Prespecified secondary analysis of a phase 3 trial in 263 patients with recurrent or metastatic nasopharyngeal carcinoma: adding camrelizumab to gemcitabine-cisplatin improved median OS (34.5 vs 26.6 months; HR 0.74) and 5-year OS (37.8% vs 24.2%).
Secondary analysisn = 263
Huang et al. Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial